WO2003068977A3 - Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden - Google Patents
Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden Download PDFInfo
- Publication number
- WO2003068977A3 WO2003068977A3 PCT/EP2002/009354 EP0209354W WO03068977A3 WO 2003068977 A3 WO2003068977 A3 WO 2003068977A3 EP 0209354 W EP0209354 W EP 0209354W WO 03068977 A3 WO03068977 A3 WO 03068977A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- component
- containing active
- constructs containing
- fusion constructs
- active sections
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK02806793.2T DK1516054T3 (da) | 2002-02-10 | 2002-08-21 | Fusionskonstruktioner der indeholder aktive afsnit af TNF-ligander |
EP02806793A EP1516054B1 (de) | 2002-02-10 | 2002-08-21 | Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden |
US10/503,999 US7736657B2 (en) | 2002-02-10 | 2002-08-21 | Fusion constructs containing active sections on TNF ligands |
AU2002333502A AU2002333502A1 (en) | 2002-02-10 | 2002-08-21 | Fusion constructs containing active sections of tnf ligands |
AT02806793T ATE450614T1 (de) | 2002-02-10 | 2002-08-21 | Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden |
DE50214059T DE50214059D1 (de) | 2002-02-10 | 2002-08-21 | Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden |
US12/756,268 US8501177B2 (en) | 2002-02-10 | 2010-04-08 | Treatment of ectodermal dysplasia with EDA1 fusion proteins |
US13/922,897 US8895003B2 (en) | 2002-02-10 | 2013-06-20 | Pharmaceutical composition comprising EDA-1 Fusion Protein |
US14/521,631 US20150098944A1 (en) | 2002-02-10 | 2014-10-23 | Fusion constructs containing active sections of tnf ligands |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10205368 | 2002-02-10 | ||
DE10205368.5 | 2002-02-10 | ||
DE10205583.1 | 2002-02-11 | ||
DE10205583A DE10205583A1 (de) | 2002-02-10 | 2002-02-11 | Fusionskonstrukte, enthaltend aktive Abschnitte von TNF-Liganden |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10503999 A-371-Of-International | 2002-08-21 | ||
US10/503,999 A-371-Of-International US7736657B2 (en) | 2002-02-10 | 2002-08-21 | Fusion constructs containing active sections on TNF ligands |
US12/756,268 Continuation US8501177B2 (en) | 2002-02-10 | 2010-04-08 | Treatment of ectodermal dysplasia with EDA1 fusion proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003068977A2 WO2003068977A2 (de) | 2003-08-21 |
WO2003068977A3 true WO2003068977A3 (de) | 2004-05-27 |
Family
ID=27735661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/009354 WO2003068977A2 (de) | 2002-02-10 | 2002-08-21 | Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden |
Country Status (4)
Country | Link |
---|---|
US (4) | US7736657B2 (de) |
EP (1) | EP1516054B1 (de) |
AU (1) | AU2002333502A1 (de) |
WO (1) | WO2003068977A2 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9017679B2 (en) | 2005-08-30 | 2015-04-28 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins |
US9499627B2 (en) | 2009-08-03 | 2016-11-22 | University Of Miami | Method for in vivo expansion of T regulatory cells |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7732131B2 (en) | 2004-08-03 | 2010-06-08 | Innate Pharma S.A. | Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor |
US9931386B2 (en) * | 2008-06-16 | 2018-04-03 | Atsuo Ochi | Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity |
WO2010056755A2 (en) * | 2008-11-11 | 2010-05-20 | Craig H Randall | Microfluidic embryo and gamete culture systems |
CA2757114C (en) | 2009-03-30 | 2019-05-21 | Universite De Lausanne | Preparation of isolated agonist anti-edar monoclonal antibodies |
EP2694550B1 (de) * | 2011-04-01 | 2019-11-27 | Universität Stuttgart | Rekombinante polypeptidmitglieder der tnf-ligandenfamilien mit antikörperbindungsdomäne und verwendungen dafür |
AU2012256174B2 (en) * | 2011-05-13 | 2016-10-27 | Edimer Pharmaceuticals, Inc. | Compositions and methods for the alteration of XLHED phenotypes |
JP6388581B2 (ja) | 2012-08-02 | 2018-09-12 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 単量体および多量体分子を生産するための方法およびその使用 |
CA2891386A1 (en) * | 2012-11-14 | 2014-05-22 | Edimer Pharmaceuticals, Inc. | Compositions and methods for the treatment of ectodermal dysplasia |
CA2897826C (en) | 2013-01-09 | 2022-09-27 | Taylor H. Schreiber | Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein |
EP3060245B1 (de) | 2013-10-22 | 2020-02-26 | EspoirXLHED Sàrl | Intraamniotische verabreichung von proteinen zur behandlung ektodermaler dysplasien |
MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6046310A (en) * | 1996-03-13 | 2000-04-04 | Protein Design Labs., Inc. | FAS ligand fusion proteins and their uses |
WO2001049866A1 (de) * | 1999-12-30 | 2001-07-12 | Apotech Research And Development Ltd. | Bi- oder oligomer eines di-, tri-, quattro- oder pentamers von rekombinanten fusionsproteinen |
US6316256B1 (en) * | 2000-01-03 | 2001-11-13 | Tr Associates, L.L.C. | Method for protein transfer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1589107T3 (da) * | 1992-08-21 | 2010-04-26 | Univ Bruxelles | Immonuglobuliner uden lette kæder |
US7115555B2 (en) * | 1998-07-09 | 2006-10-03 | Baylor College Of Medicine | Hypohidrotic ectodermal dysplasia genes and proteins |
AU3923000A (en) * | 1999-04-16 | 2000-11-02 | Amgen, Inc. | Agp-1 fusion protein compositions and methods |
AU778611B2 (en) * | 1999-08-09 | 2004-12-16 | Merck Patent Gmbh | Multiple cytokine-antibody complexes |
UA74798C2 (uk) * | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
CA2407956A1 (en) * | 2000-05-03 | 2001-11-08 | Amgen Inc. | Modified peptides as therapeutic agents |
-
2002
- 2002-08-21 US US10/503,999 patent/US7736657B2/en not_active Expired - Lifetime
- 2002-08-21 AU AU2002333502A patent/AU2002333502A1/en not_active Abandoned
- 2002-08-21 WO PCT/EP2002/009354 patent/WO2003068977A2/de not_active Application Discontinuation
- 2002-08-21 EP EP02806793A patent/EP1516054B1/de not_active Expired - Lifetime
-
2010
- 2010-04-08 US US12/756,268 patent/US8501177B2/en not_active Expired - Lifetime
-
2013
- 2013-06-20 US US13/922,897 patent/US8895003B2/en not_active Expired - Lifetime
-
2014
- 2014-10-23 US US14/521,631 patent/US20150098944A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6046310A (en) * | 1996-03-13 | 2000-04-04 | Protein Design Labs., Inc. | FAS ligand fusion proteins and their uses |
WO2001049866A1 (de) * | 1999-12-30 | 2001-07-12 | Apotech Research And Development Ltd. | Bi- oder oligomer eines di-, tri-, quattro- oder pentamers von rekombinanten fusionsproteinen |
US6316256B1 (en) * | 2000-01-03 | 2001-11-13 | Tr Associates, L.L.C. | Method for protein transfer |
Non-Patent Citations (7)
Title |
---|
BAUM PETER R ET AL: "Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 13, no. 17, 1994, pages 3992 - 4001, XP002264605, ISSN: 0261-4189 * |
BODMER J-L ET AL: "The molecular architecture of the TNF superfamily", TIBS TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER PUBLICATION, CAMBRIDGE, EN, vol. 27, no. 1, 1 January 2002 (2002-01-01), pages 19 - 26, XP004332356, ISSN: 0968-0004 * |
BULFONE-PAUS S ET AL: "AN INTERLEUKIN-2-IGG-FAS LIGAND FUSION PROTEIN SUPPRESSES DELAYED-TYPE HYPERSENSITIVITY IN MICE BY TRIGGERING APOPTOSIS IN ACTIVATED T CELLS AS A NOVEL STRATEGY FOR IMMUNOSUPPRESSION", TRANSPLANTATION, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 69, no. 7, 15 April 2000 (2000-04-15), pages 1386 - 1391, XP002942713, ISSN: 0041-1337 * |
FANSLOW W C ET AL: "Structural characteristics of CD40 ligand that determine biological function.", SEMINARS IN IMMUNOLOGY. UNITED STATES OCT 1994, vol. 6, no. 5, October 1994 (1994-10-01), pages 267 - 278, XP002264604, ISSN: 1044-5323 * |
HOLLER N ET AL: "Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 237, no. 1-2, April 2000 (2000-04-01), pages 159 - 173, XP004192503, ISSN: 0022-1759 * |
HOLLER NILS ET AL: "Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 23, no. 4, February 2003 (2003-02-01), pages 1428 - 1440, XP002258597, ISSN: 0270-7306 * |
SCHNEIDER P ET AL: "APOPTOSIS INDUCED BY DEATH RECEPTORS", PHARMACEUTICA ACTA HELVETIAE, XX, XX, vol. 74, no. 2/3, March 2000 (2000-03-01), pages 281 - 286, XP001121938, ISSN: 0031-6865 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9017679B2 (en) | 2005-08-30 | 2015-04-28 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins |
US9499627B2 (en) | 2009-08-03 | 2016-11-22 | University Of Miami | Method for in vivo expansion of T regulatory cells |
Also Published As
Publication number | Publication date |
---|---|
US20100254984A1 (en) | 2010-10-07 |
US8501177B2 (en) | 2013-08-06 |
US20150098944A1 (en) | 2015-04-09 |
US20050152872A1 (en) | 2005-07-14 |
AU2002333502A1 (en) | 2003-09-04 |
WO2003068977A2 (de) | 2003-08-21 |
EP1516054A2 (de) | 2005-03-23 |
US7736657B2 (en) | 2010-06-15 |
US20130295093A1 (en) | 2013-11-07 |
US8895003B2 (en) | 2014-11-25 |
EP1516054B1 (de) | 2009-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003068977A3 (de) | Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden | |
WO2004085478A3 (en) | Improved fc fusion proteins | |
BE2016C015I2 (de) | ||
WO1999002711A3 (en) | Fusion proteins with an immunoglobulin hinge region linker | |
WO2007048037A3 (en) | METHODS FOR GENERATING MONOVALENT IgG | |
WO2005087810A3 (en) | Dimeric fusion proteins and materials and methods for producing them | |
EP1053255A4 (de) | DREIDIMENSIONALE STRUKTUREN UND MODELLE VON Fc-REZEPTOREN UND IHRE VERWENDUNGEN. | |
DK1682583T3 (da) | Proteinkompleksdannelse under anvendelse af immunoglobulinfragment samt fremgangsmåde til fremstilling deraf | |
WO2004065540A3 (en) | Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function | |
WO2003011115A3 (en) | Peptide-based multimeric targeted contrast agents | |
IL157446A0 (en) | Increased recovery of active proteins | |
WO2003054142A3 (en) | Novel sulfurylase-luciferase fusion proteins and thermostable sulfurylase | |
WO2004020404A3 (en) | Modified transferin-antibody fusion proteins | |
WO2006020114A3 (en) | Variant fc regions | |
WO2002002626A3 (en) | Novel secreted proteins | |
WO2004020405A3 (en) | Modified transferrin fusion proteins | |
WO2005005638A3 (en) | High affinity fusion proteins (rc-scfv-fc or scfv-scfv-fc) binding cytokines, particularly il-6 & il-18 | |
ATE223229T1 (de) | Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren | |
WO2006001023A3 (en) | Chimeric proteins and uses thereof | |
WO2004108885A3 (en) | Fc chimeric proteins with anti-hiv drugs | |
WO2004087757A3 (en) | Antibodies with enhanced ability to immunomodulate cell functions | |
EP1523492A4 (de) | Igg-fc/hiv-gp120/c3d-fusionsprotein | |
WO2005051983A3 (en) | Oligomeric complexe formation of recombinant multi subunit chimeric polypeptides | |
WO2003072751A3 (en) | Expression system for human brain-specific voltage-gated sodium channel, type 1 | |
WO2004020588A3 (en) | Transferrin fusion protein libraries |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002806793 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10503999 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2002806793 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |